| 000 | 01362 a2200349 4500 | ||
|---|---|---|---|
| 005 | 20250515043410.0 | ||
| 264 | 0 | _c20080403 | |
| 008 | 200804s 0 0 eng d | ||
| 022 | _a0020-9996 | ||
| 024 | 7 |
_a10.1097/01.rli.0000242836.25299.8f _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aShamsi, Kohkan | |
| 245 | 0 | 0 |
_aA summary of safety of gadofosveset (MS-325) at 0.03 mmol/kg body weight dose: Phase II and Phase III clinical trials data. _h[electronic resource] |
| 260 |
_bInvestigative radiology _cNov 2006 |
||
| 300 |
_a822-30 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aBlood Chemical Analysis |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aGadolinium _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections |
| 650 | 0 | 4 | _aMagnetic Resonance Angiography |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOrganometallic Compounds _xadministration & dosage |
| 650 | 0 | 4 |
_aPeripheral Vascular Diseases _xblood |
| 650 | 0 | 4 | _aUrinalysis |
| 700 | 1 | _aYucel, E Kent | |
| 700 | 1 | _aChamberlin, Paul | |
| 773 | 0 |
_tInvestigative radiology _gvol. 41 _gno. 11 _gp. 822-30 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/01.rli.0000242836.25299.8f _zAvailable from publisher's website |
| 999 |
_c16612204 _d16612204 |
||